Amphastar Pharmaceuticals (AMPH) Cash from Operations Growth (3y) (2016 - 2026)
Amphastar Pharmaceuticals (AMPH) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 933.33 Mn | 643.20 Mn | 93.47 Mn | -2.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.23% |
| Mar 31, 2026 | 5.81% |
| Dec 31, 2025 | 29.23% |
| Sep 30, 2025 | 37.17% |
| Jun 30, 2025 | 132.97% |
| Mar 31, 2025 | -11.59% |
| Dec 31, 2024 | -10.47% |
| Sep 30, 2024 | 185.78% |
| Jun 30, 2024 | 29.05% |
| Mar 31, 2024 | 34.30% |
| Dec 31, 2023 | 12.20% |
| Sep 30, 2023 | 94.03% |
| Jun 30, 2023 | 22.21% |
| Mar 31, 2023 | 201.26% |
| Dec 31, 2022 | 39.14% |
| Sep 30, 2022 | 54.63% |
| Jun 30, 2022 | -62.10% |
| Mar 31, 2022 | 152.31% |
| Dec 31, 2021 | 61.97% |
| Sep 30, 2021 | -45.40% |